Literature DB >> 30613984

Fluoxetine and its metabolite norfluoxetine induce microglial apoptosis.

Kamaldeep S Dhami1, Matthew A Churchward1, Glen B Baker1, Kathryn G Todd1.   

Abstract

Inflammatory insult to the central nervous system (CNS) can lead to development of depression, and subsequently depression is the most frequent psychiatric comorbidity following ischemic stroke, often limiting recovery and rehabilitation in patients. The initiators of inflammatory pathways in the CNS are microglia activated in response to acute ischemic stress, and anti-depressants have been shown to have anti-inflammatory effects in the CNS, promoting neuronal survival following ischemic insult. We have previously shown that the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and citalopram promote neuronal survival after oxygen-glucose deprivation, an in vitro model of ischemia, by attenuating the release of glutamate and D-serine from activated microglia. Interestingly, we found that fluoxetine-treated microglial cultures contained fewer numbers of cells compared to other groups and hypothesized that fluoxetine and citalopram attenuated the release of glutamate and D-serine by promoting the apoptosis of microglia. The present study aimed to test and compare antidepressants from three distinct classes (tricyclics, monoamine oxidase inhibitors, and SSRIs) on microglial apoptosis. Primary microglia were treated with 1 μg/mL lipopolysaccharide and/or 10 μM antidepressants, and various apoptotic markers were assayed. Fluoxetine and its metabolite norfluoxetine decreased protein levels in cell lysates, decreased cell viability of microglia, and increased the expression of the apoptotic marker cleaved-caspase 3 in microglia. Live/dead nuclear staining also showed that fluoxetine- or norfluoxetine-treated cultures contained greater numbers of dying microglial cells compared to vehicle-treated cultures. Cultures treated with citalopram, phenelzine, or imipramine showed no evidence of inducing microglial apoptosis. Our results demonstrate that fluoxetine and norfluoxetine induce the apoptotic death of microglia, which may serve as a mechanism to attenuate the release of glutamate and D-serine from activated microglia. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.
© 2019 International Society for Neurochemistry.

Entities:  

Keywords:  antidepressant; fluoxetine; microglia; norfluoxetine

Mesh:

Substances:

Year:  2019        PMID: 30613984     DOI: 10.1111/jnc.14661

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Serotonin transporter-mediated molecular axis regulates regional retinal ganglion cell vulnerability and axon regeneration after nerve injury.

Authors:  Rody Kingston; Dwarkesh Amin; Sneha Misra; Jeffrey M Gross; Takaaki Kuwajima
Journal:  PLoS Genet       Date:  2021-11-04       Impact factor: 5.917

Review 2.  Modulation of microglial activation by antidepressants.

Authors:  Nicole Mariani; James Everson; Carmine M Pariante; Alessandra Borsini
Journal:  J Psychopharmacol       Date:  2022-01-29       Impact factor: 4.153

Review 3.  The role of microglia in neuropsychiatric disorders and suicide.

Authors:  Ralf Brisch; Szymon Wojtylak; Arthur Saniotis; Johann Steiner; Tomasz Gos; Jaliya Kumaratilake; Maciej Henneberg; Rainer Wolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-09-30       Impact factor: 5.760

Review 4.  LncRNA, an Emerging Approach for Neurological Diseases Treatment by Regulating Microglia Polarization.

Authors:  Xiaoyu Gao; Zilong Cao; Haifeng Tan; Peiling Li; Wenen Su; Teng Wan; Weiming Guo
Journal:  Front Neurosci       Date:  2022-07-04       Impact factor: 5.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.